Efficacy of Eribulin Monotherapy in Patients with Unresectable Angiosarcoma--A Multicenter Prospective Observational Study

Efficacy of Eribulin Monotherapy in Patients with Unresectable Angiosarcoma--A Multicenter Prospective Observational Study - Erbulin monotherapy for angiosarcoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000023331

Enrollment

Registered

2016-08-01

Start date

2016-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiosarcoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed angiosarcoma of the skin and scheduled to treat with eribulin monotherapy 2) Previous chemotherapy equal or less than 3 regimens

Exclusion criteria

Exclusion criteria: 1) Severe bone marrow suppression 2) Presence of uncontrolled hemopneumothorax 3) Pregnancy or possibility of pregnancy 4) Investigator's decision

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Secondary endpoint:response ratio, PFS, adverse events	—

Countries

Japan

Contacts

Public ContactYasuhiro Fujisawa

University of Tsukuba Dermatology

fujisan@md.tsukuba.ac.jp029-853-3128

Outcome results